Diabetes mellitus is a disorder that results from impairment of insulin action or secretion seen in chronic hyperglycemia and long-term severe vascular complications. The study aimed to determine the hypoglycemic and hepatocurative activities of Aju-mbaise on the alloxan-diabetic model in male Wistar Rat. Thirty male Wistar rats weighing 140-190g were employed for the study and grouped into six groups of five animals each. Group A received feed and distilled water only, group B diabetic control, group C received alloxan and treated with 150mg/kg of Aju-mbaise. Group D received alloxan and treated with 600mg/kg of Aju-mbaise. Aju-mbaiseextract was administered through oral gavage, and lasted for 21. Data obtained for blood glucose, Alkaline Phosphatase, Aspartate aminotransferase, Alanine aminotransferase, liver weight, and body weight were subjected to SPSS version 25 (IBM, USA, 2018). ANOVA was used to analyzed the data followed by post HOC Turkey HSD, and values were considered significant at p<0.05. The study findings revealed a non-significant (p>0.05) increase in the bodyweight in-group C and D compared to group B. Also, relative liver weight had a non-significant (p>0.05) difference in-group C, E, and F, with a significant decrease (p<0.05) in group D compared to group B. Also, aspartate aminotransferase and alkaline phosphatase showed a significant (p<0.05) difference in the treated group D, E, and F compared to group B. further, alanine aminotransferase showed a significant (p<0.05) difference in the treated group C, D, E, and F compared to group B. The blood glucose level at day 0 showed a significant (p<0.05) increase in group B, C, D, E, F when compared to group A. Day 7, 14, and 21 results revealed a significant (p<0.05) decrease in the blood glucose level in group C, D, E, and F as compared to group B. In conclusion, Aju-mbaise possesses anti-diabetic and hepatocurative activities on alloxan diabetic model in Wistar rats based on dose-dependent.